NCT03199261View on ClinicalTrials.gov

A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 23, 2016

Primary Completion Date

January 21, 2017

Study Completion Date

January 21, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

rE-4 Injection

During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.

DRUG

rE-4 Freeze-dried Powder

During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.

Trial Locations (1)

100071

The Affiliated Hospital Military Medical Sciences, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT03199261 - A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects | Biotech Hunter | Biotech Hunter